您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Corticosterone
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Corticosterone
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Corticosterone图片
CAS NO:50-22-6
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
50mg电议
100mg电议
200mg电议
500mg电议

产品名称
皮质酮
17-Deoxycortisol
11β,21-Dihydroxyprogesterone
Kendall's compound B
产品介绍
Corticosterone (17-Deoxycortisol) 是一种具有口服活性的,由肾上腺皮质产生的糖皮质激素,在调节边缘系统 (包括海马体、前额叶皮层和杏仁核) 的神经元功能方面起着重要作用。皮质酮可通过SGK诱导的GDI磷酸化增加Rab介导的AMPAR膜运输。Corticosterone 还能干扰树突状细胞的成熟,具有较好的免疫抑制活性。
生物活性

Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases theRab-mediatedAMPARmembrane traffic viaSGK-induced phosphorylation ofGDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect[1][2][3][4].

IC50& Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Corticosterone (100 nM; 30 min) via SGK phosphorylation of GDI at Ser-213, increases the formation of GDI-Rab4 complex, facilitating the functional cycle of Rab4 and Rab4-mediated recycling of AMPARs to the synaptic membrane[1].
Corticosterone (CORT) (1 μM; 48 h) shows good immunosuppressive properties (functionally compromises maturation of BMDC), which impairs LPS-induced up-regulation of maturation-associated markers (MHC class II, B7.2, B7.1 and CD40)[2].

Cell Viability Assay[1]

Cell Line:HEK293 cells
Concentration:100 nM
Incubation Time:30 min
Result:Caused a significant enhancement of mEPSC amplitude (mEPSC represents the postsynaptic response to release of individual vesicles of glutamate).
Increased the transmission of glutamatergic, and increased synaptic AMPAR currents via a Rab4-dependent mechanism.
Profoundly increased surface GluR1 cluster density, cluster size and cluster fluorescence intensity.
Significantly increased the amount of Rab4 that binded to WT-GDI, S45A-GDI, or S121A-GDI but not S213A-GDI.
Induced the phosphorylation of GST-WTGDI, GST-S45AGDI, and GST-S121AGDI, but not GST-S213AGDI, and this effect was blocked in cells transfected with SGK1 small interfering RNA.
Increased AMPAR surface expression via a mechanism dependent on GDI phosphorylation.

Cell Viability Assay[2]

Cell Line:BMDC cells
Concentration:1 μM
Incubation Time:48 h
Result:Completely blocked the expression of MHC class II and B7.2 that induced by LPS, and maximally impaired BMDC cells maturation at 12 h.
Reduced B7.1 by 50%, and slightly down-regulated CD40.
体内研究
(In Vivo)

Corticosterone results in a marked reduction in the ability of BMDC cells to prime naive CD8+T cells in vivo[2].
Corticosterone (0.03 or 1 mg/kg; s.c.; single) downregulates expression of BDNF mRNA in dentate gyrus and CA1 of rats[3].
Corticosterone (2.6 mg/kg; in animal feedings; 8 days) restores ethanol intake and preference to approximately normal preoperative levels in adrenalectomy (ADX) rats[4].

Animal Model:Adult male Wistar rats (150-170 g; adrenalectomized)[3].
Dosage:0.03 or 1 mg/kg
Administration:Subcutaneous injection; single.
Result:Decreased expression of BDNF mRNA in dentate gyrus, with 25% and 50% lower for dosages of 0.03 and 1 mg/kg, respectively (3 h after administration).
Reduced approximately 40% BDNF mRNA level as compared to the t=0 h control group (3 h after administration), but the level increased by 100% when 12 h after administration (compared to t=3 h and t=6 h group).
Animal Model:Male Wistar rats (3-week-old; adrenalectomized)[4].
Dosage:2.6 mg/kg
Administration:In animal feedings; 8 days.
Result:Restored ethanol intake and preference of adrenalectomy (ADX) rats to approximately normal preoperative levels and to the levels observed in the sham-operated group (SH) rats.
Clinical Trial
分子量

346.46

性状

Solid

Formula

C21H30O4

CAS 号

50-22-6

中文名称

皮质酮;皮质甾酮;皮质脂酮

结构分类
  • Steroids
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL(288.63 mM;Need ultrasonic)

Ethanol : 14.29 mg/mL(41.25 mM;Need ultrasonic)

H2O : 0.67 mg/mL(1.93 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.8863 mL14.4317 mL28.8634 mL
5 mM0.5773 mL2.8863 mL5.7727 mL
10 mM0.2886 mL1.4432 mL2.8863 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 20%HP-β-CD   5% Cremophor EL

    Solubility: 5 mg/mL (14.43 mM); Clear solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 20%HP-β-CDin saline

    Solubility: 4 mg/mL (11.55 mM); Suspended solution; Need ultrasonic

  • 3.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
  • 4.

    请依序添加每种溶剂: 10% DMSO    90% (20%SBE-β-CDin saline)

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 5.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 6.

    请依序添加每种溶剂: 0.5%CMC-Na/saline water

    Solubility: 2 mg/mL (5.77 mM); Suspended solution; Need ultrasonic and warming and heat to 60℃

  • 7.

    请依序添加每种溶剂: 10% EtOH    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 1.43 mg/mL (4.13 mM); Clear solution

    此方案可获得 ≥ 1.43 mg/mL (4.13 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 14.3 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
  • 8.

    请依序添加每种溶剂: 10% EtOH    90% (20%SBE-β-CDin saline)

    Solubility: ≥ 1.43 mg/mL (4.13 mM); Clear solution

    此方案可获得 ≥ 1.43 mg/mL (4.13 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 14.3 mg/mL 的澄清 EtOH 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 9.

    请依序添加每种溶剂: 10% EtOH    90%corn oil

    Solubility: ≥ 1.43 mg/mL (4.13 mM); Clear solution

    此方案可获得 ≥ 1.43 mg/mL (4.13 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 14.3 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。